About this Research Topic
Chemotherapy resistance, both primary and secondary, represents a significant barrier to the effective treatment of gastrointestinal (GI) tumors, including gastric, colorectal cancers, and so on. Primary resistance refers to the inherent non-responsiveness of tumors to initial chemotherapy, while secondary resistance develops after an initial period of therapeutic efficacy. These resistance mechanisms are multifaceted, involving genetic mutations, epigenetic modifications, alterations in the tumor microenvironment, and changes in drug metabolism pathways.
Recent advancements in the field have provided deeper insights into these complex mechanisms over the years. High-throughput sequencing technologies have elucidated specific genetic mutations associated with resistance, paving the way for personalized treatment strategies. Additionally, non-coding RNAs, including microRNAs and circular RNAs, have been identified as key regulators of drug resistance, offering new targets for therapeutic intervention. The tumor microenvironment, particularly the role of cancer-associated fibroblasts and immune cells, has also been recognized as a crucial factor influencing chemotherapy response. Furthermore, the emergence of immunotherapy has introduced novel strategies to overcome chemoresistance, either as monotherapy or in combination with conventional chemotherapy.
This Research Topic aims to comprehensively explore the underlying mechanisms of chemotherapy resistance in GI tumors and to discuss innovative strategies to counteract these resistance pathways. Emphasis will be placed on genomic and epigenomic discoveries, the interplay between the tumor microenvironment and resistance, and the integration of new therapeutic modalities. By addressing these critical issues, we aim to provide valuable insights that will enhance clinical practice and improve outcomes for patients with gastrointestinal cancers.
Recent advancements in the field have provided deeper insights into these complex mechanisms over the years. High-throughput sequencing technologies have elucidated specific genetic mutations associated with resistance, paving the way for personalized treatment strategies. Additionally, non-coding RNAs, including microRNAs and circular RNAs, have been identified as key regulators of drug resistance, offering new targets for therapeutic intervention. The tumor microenvironment, particularly the role of cancer-associated fibroblasts and immune cells, has also been recognized as a crucial factor influencing chemotherapy response. Furthermore, the emergence of immunotherapy has introduced novel strategies to overcome chemoresistance, either as monotherapy or in combination with conventional chemotherapy.
This Research Topic aims to comprehensively explore the underlying mechanisms of chemotherapy resistance in GI tumors and to discuss innovative strategies to counteract these resistance pathways. Emphasis will be placed on genomic and epigenomic discoveries, the interplay between the tumor microenvironment and resistance, and the integration of new therapeutic modalities. By addressing these critical issues, we aim to provide valuable insights that will enhance clinical practice and improve outcomes for patients with gastrointestinal cancers.
Keywords: chemotherapy resistance, gastrointestinal cancers, mechanism, immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
